Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
333.52
-1.54 (-0.46%)
Sep 30, 2026, 2:08 PM EDT - Market open
Krystal Biotech Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Krystal Biotech stock has a consensus rating of "Strong Buy" and an average price target of $392.11. The average 1-year stock price forecast is 17.57% higher than the current stock price, while the lowest is $284 (-14.85%) and the highest is $474 (+42.12%).
Price Target: $392.11 (+17.57%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Krystal Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 9 | 9 | 10 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 10 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Buy Initiates $441 | Buy | Initiates | $441 | +32.23% | Sep 24, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $392 → $400 | Buy | Reiterates | $392 → $400 | +19.93% | Sep 21, 2026 |
| RBC Capital | RBC Capital | Buy Initiates $400 | Buy | Initiates | $400 | +19.93% | Aug 14, 2026 |
| Wolfe Research | Wolfe Research | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Aug 12, 2026 |
| Citi | Citi | Buy Maintains $378 → $386 | Buy | Maintains | $378 → $386 | +15.74% | Aug 4, 2026 |
Financial Forecast
Revenue This Year
511.06M
from 389.13M
Increased by 31.33%
Revenue Next Year
651.87M
from 511.06M
Increased by 27.55%
EPS This Year
7.87
from 6.84
Increased by 14.99%
EPS Next Year
9.32
from 7.87
Increased by 18.49%
EPS and Forward PE are based on non-GAAP adjusted numbers.